Member Info for Wiggly

Good asset to this BB. HE/she confirmed the KOL speakers weeks ago also.

13th

That won't be our concern as it'll be licensed out shortly for mega bucks

Only if you are a trader looking for a couple of %.

Yeh, what a fool. Mixing Bach with Tap!!

Dr William Tap is:

1. completely impartial and;
2, the leading global subject matter expert covering treatment of STS.

Dr William Tap Chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, USA

Yes, because the CEO already informed the market of 6 x Biopsies with a 100% hit rate - all including Therapeutic levels of Dox. He also informed the market of significantly reduced side effects and a plan to dose much higher.

However, the finer details have not yet been disclosed but based on the below I am sure we are going to get the finer details later today!

Also, has it been discussed here that the DETAILED REVIEW of the ongoing ALS-6000-101 is going to focus specifically on SOFT TISSUE SARACOMA



The event will include a DETAILED REVIEW of the ongoing ALS-6000-101 Phase 1a clinical trial of AVA6000, Avacta's lead pre|CISION™ tumour targeted form of the chemotherapy drug Doxorubicin, IN SOFT TISSUE SARACOMA, as well as an update on preclinical programmes.

Thats what I thought - only speculation. It is surprising that we do not have official confirmation. Would they be named on the invitation?

Do we have 100% confirmation of who the KOL's will be ?

Must be a leak!

Massive strength driving SP.

This now confirmed?

not sure but MM currently happy to take all of my shares, so they must be working for a large buyer.

AS mentioned during the results meeting that hair loss had not been seen with any patient. He then stated the following within the last RNS:

'A marked reduction in the incidence and severity of the typical toxicities associated with the standard doxorubicin chemotherapy administration. Typical toxicities include alopecia

Dox found in 100% of Biopsies, 6 out of 6.

Dox in Tumor measured at significant 'therapeutic' levels.

Side effects including hair loss completely removed.

Has the above news finally leaked or is there some other news that is leaking?

Many pharma assets/companies get taken out at the pre-clinical stage and many more at Clinical stage phase 1.

The Avacta phase 1 data has surpassed the company expectations; thus I really think it is now only a matter of time before big pharma make a first move.

I noticed he liked the LinkedIn post from Dr Smith

It's actually far from rampy pumpy.

Its a good source, well managed (unlike this place) with good contributors and thankfully not infested with Fud posters.

“SQ3370 enables previously unachievable levels of Dox exposure at the tumor”

How can they state this if Dox was only found to be present in 1/6 Tumors?

'Congrats to our team at Avacta - fantastic news moving this technology forward for patients.'

There is also another interesting like from a 2nd Lonza employee.

Vidya P, Business Development Manager at Lonza Biologics

2 x likes Certainly increases the likelihood of some form of engagement on-going.

Another interesting like from a director at Pebmond.

Business Development and Licensing
Need support to acquire, divest or license a product or project? That's what we do.

Pebmond Associates provides solutions for developing and growing pharma companies. These include business development services (particularly focussing on deal structuring and risk mitigation of partnerships and licensing agreements), board and strategic advice/

https://www.pebmonduk.com/